ICU Medical, Inc. (ICUI) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. ICU Medical, Inc. develops, manufactures, and sells medical products for infusion therapy, vascular access, and vital care. The company operates as a single reportable segment. Key recent developments include the May 2025 sale of a 60% interest in its IV Solutions business to Otsuka Pharmaceutical Factory America, Inc. (OPF), creating a joint venture, and the October 2025 refinancing of its credit facilities.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Value (in millions) |
|---|---|
| Total Revenues | $1,081.9 |
| Gross Profit | $441.3 |
| Gross Margin | 40.8% |
| Net Income | $49.2 |
| Diluted EPS | $1.96 |
| Operating Cash Flow | $119.1 |
| Cash and Cash Equivalents (Ending) | $298.3 |
| Total Debt (Principal) | $1,239.8 |
Material Changes vs. Prior Period
- Revenue: Total revenue decreased 6.2% year-over-year (YoY) to $1,081.9 million, primarily due to the divestiture of the IV Solutions business. On a constant currency basis, Consumables revenue grew 3.6% and Infusion Systems revenue grew 9.0%, while Vital Care revenue declined 48.5% due to the sale.
- Profitability: Net income increased significantly to $49.2 million from $19.9 million in the prior year period. This improvement was driven by a 4.5 percentage point increase in gross margin (to 40.8%), largely attributable to $18.9 million in tariff refunds recognized in Q2 2026 and the removal of lower-margin IV Solutions revenue.
- Expenses: Restructuring and integration expenses increased to $38.1 million (from $32.9 million YoY), driven by facility closures and severance costs related to the Smiths Medical integration. SG&A expenses decreased 3.2% YoY due to lower dealer fees, IT expenses, and facility costs.
- Debt: The company prepaid $45.3 million on Term Loan B in Q2 2026. Total long-term debt principal stands at approximately $1.24 billion.
Guidance, Outlook, and Risks
- Capital Expenditures: Management expects 2026 capital expenditures to be approximately $85 million, at the low end of the previously disclosed range.
- Tariffs and Refunds: Following a Supreme Court ruling in February 2026, the company recognized $18.9 million in tariff refunds. However, new tariffs under Section 301 of the Trade Act of 1974 were announced in July 2026, creating uncertainty regarding future import costs.
- Regulatory Matters:
- 2021 Warning Letter: Closed by the FDA in February 2026. Remaining accrued costs for field corrective actions are approximately $16.6 million.
- 2025 Warning Letter: Issued regarding modifications to MedFusion and CADD infusion pumps. The company withdrew 510(k) applications for additional testing and plans to resubmit. No loss contingency has been recorded as the outcome is not yet probable or estimable.
- Liquidity: The company maintains a $500 million revolving credit facility with no outstanding borrowings as of June 30, 2026. It remains in compliance with all financial covenants.
Investor Verification Checklist
- Tariff Exposure: Verify the impact of new Section 301 tariffs announced in July 2026 on future cost of goods sold and margins.
- Regulatory Resolution: Monitor the timeline and success of the resubmitted 510(k) applications for MedFusion and CADD pumps following the 2025 Warning Letter.
- Joint Venture Performance: Review the financial performance of the Otsuka ICU Medical LLC joint venture, which accounts for a portion of equity earnings.
- Debt Maturity Profile: Assess the "springing maturity" provision on the Term Loan A and Revolver, which could accelerate repayment if Term Loan B is not paid down by 91 days prior to its 2029 maturity.
- Restructuring Costs: Confirm that expected restructuring costs decrease in the remainder of 2026 as management projects.